Price
No data yet.
Signal Score (90d)
112Revenue
$343.49M+38.04%Quote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $1.37B | $47.05M | $1.52 |
| 2024 | $1.31B | $132.42M | $4.29 |
| 2023 | $1.24B | $64.46M | $2.10 |
| 2022 | $1.05B | $-80.58M | $-2.68 |
| 2021 | $1.01B | $62.54M | $2.14 |
Social Signal Score
Earnings
Wed, Nov 4(in 3 months)
Consensus estimate $1.00 per share
Typical surprise +8.5% (median, so one quarter with a near-zero estimate can't distort it)
- Wed, Jul 29$1.38 vs $1.11beat
- Wed, Apr 29$0.89 vs $0.82beat
- Wed, Jan 28$1.43 vs $1.32beat
- Wed, Nov 5$1.08 vs $1.05beat
- Wed, Jul 30$1.15 vs $1.13beat
- Wed, Apr 30$0.95 vs $0.81beat
Estimates and results for CNMD via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by CNMD officers and directors.
- Bought
- —
- Sold
- $527k
0 trades
6 trades
- Glaze Richardsold
- Garner Todd Wsold
- Farkas Charlessold
- Farkas Charlessold
- Garner Todd Wsold
- Farkas Charlessold
94 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Valuation
Project earnings forward and see what return today's price implies.
Seeded from CNMD's reported EPS growth of -8.2% a year over 4 years.
- EPS in 5 years
- $0.99
- Implied price
- $26.69
- Return from $49.25
- -11.5% a year
To earn 15.0% a year on these assumptions you'd need to buy at $13.27 — -73.1% below today's price.
How sensitive is that answer?
Annual return across nearby assumptions. If the result is only attractive in one corner, that is the finding.
| growth \ P/E | 19 | 23 | 27 | 31 | 35 |
|---|---|---|---|---|---|
| -18.2% | -26.5% | -23.7% | -21.2% | -19.0% | -17.0% |
| -13.2% | -22.0% | -19.0% | -16.4% | -14.0% | -11.9% |
| -8.2% | -17.5% | -14.3% | -11.5% | -9.1% | -6.8% |
| -3.2% | -13.0% | -9.7% | -6.7% | -4.1% | -1.7% |
| 1.8% | -8.6% | -5.0% | -1.9% | 0.9% | 3.3% |
This is arithmetic on assumptions you chose, not a forecast or a recommendation. It ignores dividends, buybacks, share issuance and debt, and it assumes a company still earning money in 5 years. Change any input and the answer changes a lot — that sensitivity is the honest result, not a flaw in the model.
Mentions (4)
- Newszacks.com·4h ago·Positive
CNMD Jumps 16% in a Month as Investors Assess Whether It Can Last CNMD's 16% monthly rally is backed by stronger growth, margin gains and raised earnings guidance, but cash-flow and execution risks remain.
View source ↗ - Newszacks.com·4h ago·Positive
Can CONMED's Raised 2026 EPS Outlook Reinforce Its Growth Momentum? CONMED raised its 2026 adjusted EPS outlook after a strong second quarter, but slower organic growth and higher financing costs keep the setup mixed.
View source ↗ - Newszacks.com·4h ago·Neutral
Is CNMD a Buy Now as Low Valuation Meets Persistent Execution Risk? CNMD's low valuation and improved earnings outlook strengthen its appeal, but cash-flow pressure and execution risks keep the buy case measured.
View source ↗ - Newszacks.com·5h ago·Neutral
Here's Why You Should Retain CONMED Stock in Your Portfolio Now CONMED's growth outlook is supported by Buffalo Filter, BioBrace and organic momentum, though slower AirSeal growth and tariffs remain key risks.
View source ↗